echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > JCO: Digital Breast Cancer Course Management Based on Electronic Patient-Reported Outcome (ePRO) Monitoring and Automated Management of Intervention Reminders (eRAPID Study)

    JCO: Digital Breast Cancer Course Management Based on Electronic Patient-Reported Outcome (ePRO) Monitoring and Automated Management of Intervention Reminders (eRAPID Study)

    • Last Update: 2022-05-22
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Breast cancer is one of the common malignant tumors threatening women's health and the leading cause of cancer-related deaths in women worldwide


    breast cancer

    The Journal of Clinical Oncology, a leading international oncology journal, reported the results of a phase III randomized controlled trial conducted by researchers at the University of Leeds, St.


    (Image source: Journal of Clinical Oncology)

    research method

    research method

    The subjects of the study were cancer patients who started chemotherapy, most of them were breast cancer patients, and the rest were gynecological cancer and colorectal cancer patients


    Colorectal Cancer Trials Registry: ISRCTN88520246.


    manage

    eRAPID group: On the basis of routine care, patients were also managed based on the ePAPID system


    The eRAPID system combines ePRO symptom reporting with customized clinical algorithms to provide patients with automated, severity-based recommendations to support patients in self-management or contacting the hospital


    Main outcome: Symptom control assessed at 6, 12, and 18 weeks (functional assessment of cancer care, physical fitness subscale FACT-PWB)


    Quality of life QLQ-C30

    Among the participants, there were 508 patients (73.


    Subgroup analysis found a significant benefit in the non-metastatic group at week 6 (P = 0.


    Results showed that real-time monitoring via the ePRO system improved physical health (weeks 6 and 12) and self-efficacy (week 18) in a primarily curative patient population without increasing hospital workload


    Research Implications

    Research Implications

    These findings demonstrate that remote real-time monitoring is feasible in routine cancer care, especially in the context of the COVID-19 pandemic; an alternative digital care model during therapeutic chemotherapy that can help cancer patients with mild to moderate symptoms Improve physical condition, reduce hospital visits, and even improve quality of life and long-term survival


    COVID-19

    In the future, the digital clinical trial (DCT) model will become more and more mature with continuous exploration


    Research design

    Original source:

    Absolom K, Warrington L, Hudson E, Hewison J, Morris C, Holch P, Carter R, Gibson A, Holmes M, Clayton B, Rogers Z, McParland L, Conner M, Glidewell L, Woroncow B, Dawkins B, Dickinson S , Hulme C, Brown J, Velikova G.


    Basch E, Leahy AB, Dueck AC.




    leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.